David Haselbach
Max Planck Society
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David Haselbach.
Cell | 2016
Nicholas Brown; Ryan VanderLinden; Edmond R. Watson; Florian Weissmann; Alban Ordureau; Kuen-Phon Wu; Wei Zhang; Shanshan Yu; P. Y. Mercredi; Joseph S. Harrison; Iain Davidson; Renping Qiao; Yuancheng Lu; Prakash Dube; Michael R. Brunner; Christy Rani R. Grace; Darcie J. Miller; David Haselbach; Marc A. Jarvis; Masaya Yamaguchi; D. Yanishevski; Georg Petzold; Sachdev S. Sidhu; Brian Kuhlman; Marc W. Kirschner; J. W. Harper; Jan-Michael Peters; Holger Stark; Brenda A. Schulman
Protein ubiquitination involves E1, E2, and E3 trienzyme cascades. E2 and RING E3 enzymes often collaborate to first prime a substrate with a single ubiquitin (UB) and then achieve different forms of polyubiquitination: multiubiquitination of several sites and elongation of linkage-specific UB chains. Here, cryo-EM and biochemistry show that the human E3 anaphase-promoting complex/cyclosome (APC/C) and its two partner E2s, UBE2C (aka UBCH10) and UBE2S, adopt specialized catalytic architectures for these two distinct forms of polyubiquitination. The APC/C RING constrains UBE2C proximal to a substrate and simultaneously binds a substrate-linked UB to drive processive multiubiquitination. Alternatively, during UB chain elongation, the RING does not bind UBE2S but rather lures an evolving substrate-linked UB to UBE2S positioned through a cullin interaction to generate a Lys11-linked chain. Our findings define mechanisms of APC/C regulation, and establish principles by which specialized E3-E2-substrate-UB architectures control different forms of polyubiquitination.
Proceedings of the National Academy of Sciences of the United States of America | 2016
Renping Qiao; Florian Weissmann; Masaya Yamaguchi; Nicholas Brown; Ryan VanderLinden; Richard Imre; Marc A. Jarvis; Michael R. Brunner; Iain Davidson; Gabriele Litos; David Haselbach; Karl Mechtler; Holger Stark; Brenda A. Schulman; Jan-Michael Peters
Significance The ability of eukaryotic cells to pass their genomes properly from one cell generation to the next depends on the 1.2-MDa ubiquitin ligase complex APC/C (anaphase-promoting complex/cyclosome) and on the correct timing of its activation by the substrate adaptor CDC20 (cell division cycle 20). Although it has been known for two decades that mitotic APC/C phosphorylation is required for its activation by CDC20, the mechanistic basis of this process remained unknown, in part because the existence of numerous phospho-sites on APC/C made systematic mutagenesis approaches difficult. Here we have used the biGBac technique for the rapid assembly of multigene expression constructs to overcome this limitation and discovered that APC/C contains an autoinhibitory loop region that prevents CDC20 binding until it becomes phosphorylated in mitosis. Chromosome segregation and mitotic exit are initiated by the 1.2-MDa ubiquitin ligase APC/C (anaphase-promoting complex/cyclosome) and its coactivator CDC20 (cell division cycle 20). To avoid chromosome missegregation, APC/CCDC20 activation is tightly controlled. CDC20 only associates with APC/C in mitosis when APC/C has become phosphorylated and is further inhibited by a mitotic checkpoint complex until all chromosomes are bioriented on the spindle. APC/C contains 14 different types of subunits, most of which are phosphorylated in mitosis on multiple sites. However, it is unknown which of these phospho-sites enable APC/CCDC20 activation and by which mechanism. Here we have identified 68 evolutionarily conserved mitotic phospho-sites on human APC/C bound to CDC20 and have used the biGBac technique to generate 47 APC/C mutants in which either all 68 sites or subsets of them were replaced by nonphosphorylatable or phospho-mimicking residues. The characterization of these complexes in substrate ubiquitination and degradation assays indicates that phosphorylation of an N-terminal loop region in APC1 is sufficient for binding and activation of APC/C by CDC20. Deletion of the N-terminal APC1 loop enables APC/CCDC20 activation in the absence of mitotic phosphorylation or phospho-mimicking mutations. These results indicate that binding of CDC20 to APC/C is normally prevented by an autoinhibitory loop in APC1 and that its mitotic phosphorylation relieves this inhibition. The predicted location of the N-terminal APC1 loop implies that this loop controls interactions between the N-terminal domain of CDC20 and APC1 and APC8. These results reveal how APC/C phosphorylation enables CDC20 to bind and activate the APC/C in mitosis.
Nature Methods | 2015
Ashwin Chari; David Haselbach; Jan-Martin Kirves; Juergen Ohmer; Elham Paknia; Niels Fischer; Oleg M. Ganichkin; Vanessa Möller; Jeremiah J. Frye; Georg Petzold; Marc A. Jarvis; Michael Tietzel; Clemens Grimm; Jan-Michael Peters; Brenda A. Schulman; Kai Tittmann; Jürgen Markl; Utz Fischer; Holger Stark
Molecular machines or macromolecular complexes are supramolecular assemblies of biomolecules with a variety of functions. Structure determination of these complexes in a purified state is often tedious owing to their compositional complexity and the associated relative structural instability. To improve the stability of macromolecular complexes in vitro, we present a generic method that optimizes the stability, homogeneity and solubility of macromolecular complexes by sparse-matrix screening of their thermal unfolding behavior in the presence of various buffers and small molecules. The method includes the automated analysis of thermal unfolding curves based on a biophysical unfolding model for complexes. We found that under stabilizing conditions, even large multicomponent complexes reveal an almost ideal two-state unfolding behavior. We envisage an improved biochemical understanding of purified macromolecules as well as a substantial boost in successful macromolecular complex structure determination by both X-ray crystallography and cryo-electron microscopy.
Molecular BioSystems | 2011
Daniela M. Köster; David Haselbach; Hans Lehrach; Harald Seitz
Sensitive detection assays are a prerequisite for the analysis of small amounts of samples derived from biological material. There is a great demand for highly sensitive and robust detection techniques to analyze biomolecules. The combination of catalytic active DNA (DNAzyme) with a peroxidase activity with rolling circle amplification (RCA) is a promising alternative to common detection systems. The rolling circle amplification leads to a product with tandemly linked copies of DNAzymes. The continuous signal generation of the amplified DNAzymes results in an increased sensitivity. The combination of two amplification reactions, namely RCA and DNAzymes, results in increased signal intensity by a factor of 10(6). With this approach the labeling of samples can be avoided. The advantage of the introduced assay is the usage of nucleic acids as biosensors for the detection of biomolecules. Coupling of the analyte molecule to the detection molecules allows the direct detection of the analyte molecule. The described label-free hotpot assay has a broad potential field of applications. The hotpot assay can be adapted to detect and analyze RNA, DNA and proteins down to femtomolar concentrations in a miniaturized platform with a total reaction solution of 50 nl. The applicability of the assay for diagnostics and research will be shown with a focus on high throughput systems using a nano-well platform.
Nature Communications | 2017
David Haselbach; Jil Schrader; Felix Lambrecht; Fabian Henneberg; Ashwin Chari; Holger Stark
The proteasome holoenzyme is the major non-lysosomal protease; its proteolytic activity is essential for cellular homeostasis. Thus, it is an attractive target for the development of chemotherapeutics. While the structural basis of core particle (CP) inhibitors is largely understood, their structural impact on the proteasome holoenzyme remains entirely elusive. Here, we determined the structure of the 26S proteasome with and without the inhibitor Oprozomib. Drug binding modifies the energy landscape of conformational motion in the proteasome regulatory particle (RP). Structurally, the energy barrier created by Oprozomib triggers a long-range allosteric regulation, resulting in the stabilization of a non-productive state. Thereby, the chemical drug-binding signal is converted, propagated and amplified into structural changes over a distance of more than 150 Å from the proteolytic site to the ubiquitin receptor Rpn10. The direct visualization of changes in conformational dynamics upon drug binding allows new ways to screen and develop future allosteric proteasome inhibitors.
Molecular Cell | 2016
Masaya Yamaguchi; Ryan VanderLinden; Florian Weissmann; Renping Qiao; Prakash Dube; Nicholas Brown; David Haselbach; Wei Zhang; Sachdev S. Sidhu; Jan-Michael Peters; Holger Stark; Brenda A. Schulman
Proceedings of the National Academy of Sciences of the United States of America | 2013
Thomas Monecke; David Haselbach; Béla Voß; Andreas Russek; Piotr Neumann; Emma Thomson; Ed Hurt; Ulrich Zachariae; Holger Stark; Helmut Grubmüller; Achim Dickmanns; Ralf Ficner
Cell | 2017
Karl Bertram; Dmitry E. Agafonov; Olexandr Dybkov; David Haselbach; Majety N. Leelaram; Cindy L. Will; Henning Urlaub; Berthold Kastner; Reinhard Lührmann; Holger Stark
Structure | 2013
Nicole Dölker; Clement E. Blanchet; Béla Voß; David Haselbach; Christian Kappel; Thomas Monecke; Dmitri I. Svergun; Holger Stark; Ralf Ficner; Ulrich Zachariae; Helmut Grubmüller; Achim Dickmanns
Cell | 2018
David Haselbach; Ilya Komarov; Dmitry E. Agafonov; Klaus Hartmuth; Benjamin Graf; Olexandr Dybkov; Henning Urlaub; Berthold Kastner; Reinhard Lührmann; Holger Stark